Monitor for any future board-level strategic shifts given the appointment of a director with clinical development and M&A experience, but no immediate catalyst from this routine governance change.
SPRO drugs
SPRO drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $1.02entry
- T+1 · 5d ago −1.96%α −1.61% · $1.00
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Spero Therapeutics disclosed the resignation of director Patrick Vink, M.D., effective November 10, 2026, and the immediate appointment of William Ho, M.D., Ph.D., as a Class II director to fill the vacancy. Dr. Ho, a former Chief Medical Officer of RAPT Therapeutics, brings clinical development experience and received a standard compensation package including a $45,000 annual cash retainer and an option for 100,000 shares vesting over one year. The resignation was stated to be without any dispute with the company, and the board vacancy was filled concurrently, making this a routine governance change.
Key Facts
- Patrick Vink, M.D., resigned as Class II director and committee chair effective November 10, 2026, with no dispute or disagreement cited.
- William Ho, M.D., Ph.D., appointed as Class II director effective November 10, 2026, to fill the vacancy.
- Dr. Ho was also appointed to the Development Committee.
- Dr. Ho receives an annual cash retainer of $40,000 for board service plus $5,000 for Development Committee service.
- Dr. Ho was granted an option to purchase 100,000 shares of common stock, vesting monthly over one year.
- Dr. Ho previously served as Chief Medical Officer of RAPT Therapeutics, which was acquired by GSK for $2.2 billion in March 2026.
Financial Impact
Standard director compensation: $45,000 annual cash retainer and 100,000 share option grant vesting over one year.
Risk Factors
- No material risks identified from this routine board change.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-455789 |
| Document: 0001193125-26-455789-index-headers.html | 0001193125-26-455789 |
| Document: 0001193125-26-455789-index.html | 0001193125-26-455789 |
| Document: 0001193125-26-455789.txt | 0001193125-26-455789 |
Track record
17 reports on SPRO
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Nov 10, 20266d ago 8-K Neutral 2/10 Viewing Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
- Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
- Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
- Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
- Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers